LEXINGTON, Mass.--(BUSINESS WIRE)--May 2, 2006--Critical Therapeutics, Inc. (Nasdaq: CRTX - News) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s proposal to submit the New Drug Application (NDA) for its controlled-release (CR) formulation of zileuton with six months of primary and accelerated stability data and provide additional stability data during the review period without impacting the action date by the FDA.
